SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?


To: Eagle who wrote (26524)10/6/2005 8:10:26 AM
From: ~digs  Read Replies (1) | Respond to of 48463
 
Oct. 6, 2005--SIGA Technologies, Inc. (NASDAQ: SIGA - News) today announced that the company's lead smallpox compound, SIGA-246, completely protected golden ground squirrels from lethal doses of monkeypox virus. Monkeypox virus is closely related to human smallpox virus, and causes a similar disease in both monkeys and humans. SIGA-246, administered orally, demonstrated significant antiviral activity against the golden ground squirrel model of monkeypox disease. The study was conducted in the BSL-3 facility at the University of Texas Medical Branch (UTMB). SIGA had announced in October 2004 that it had established the efficacy of SIGA-246 in several mouse models. biz.yahoo.com



To: Eagle who wrote (26524)10/6/2005 10:23:07 AM
From: Bucky Katt  Respond to of 48463
 
No, was there anything new in the piece?